logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. High cost factors for leukaemia and lymphoma patients : a new analysis of costs within these diagnosis related groups.

    Article - En anglais

    Study objective-To determine high cost factors to help managers and clinicians to analyse the reasons of adverse costs and provide indications for financial negotiation.

    Design-To locate high cost or long stay patients, the analysis was designed on the basis of a mixture of Weibull distributions.

    In this new model, the proportion of high cost patients was expressed according to the multinomial logistic regression, permitting the determination of high cost factors.

    Setting-The 1993 French reference database, constituted in the framework of the national study of DRG costs, conducted by the French Ministry of Health.

    The database of discharge abstracts recorded in 1993 in the Dijon public teaching hospital.

    Participants-The analyses were based on 1352 abstracts from the French reference database and 368 from the Dijon database concerning patients, aged 18 and over, suffering from leukaemia and lymphoma.

    Main results-High cost and long stay factors were the same : number of stays, death, transfer, acute leukaemia, neutropenia, septicaemia, high dose aplastic chemotherapy, central venous catheterisation, parenteral nutrition, protected or laminar airflow room, blood transfusion, and intravenous antibiotherapy.

    Conclusions-Taking into account high cost predictive factors, as shown in the case of leukaemia and lymphoma patients, would help to reduce the adverse effects of a prospective payment system.

    Mots-clés Pascal : Homme, France, Europe, Economie santé, Analyse coût, Méthodologie, Hospitalisation, Analyse multivariable, Leucémie, Lymphome, Modèle statistique, Temps séjour, Hémopathie maligne, Groupe homogène malades, PMSI

    Mots-clés Pascal anglais : Human, France, Europe, Health economy, Cost analysis, Methodology, Hospitalization, Multivariate analysis, Leukemia, Lymphoma, Statistical model, Residence time, Malignant hemopathy

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 99-0127683

    Code Inist : 002B30A01B. Création : 16/11/1999.